Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
APYX
Strong SellSinkerApyx Medical Corporation · Healthcare · United States · $130M · Avg Vol: $417K/d
COMPANY DESCRIPTION
Apyx Medical Corporation develops and commercializes advanced energy devices, with its flagship J-Plasma/Renuvion technology providing unique cold plasma energy for skin tightening and soft tissue coagulation in cosmetic and surgical applications. The company's competitive moat is centered on its proprietary J-Plasma technology, which offers differentiated clinical outcomes and has established a significant niche within the rapidly growing aesthetic and surgical markets. Apyx Medical is an innovator, leveraging its intellectual property to drive adoption in high-value medical procedures.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 44.5M | 52.3M | 48.1M | 52.8M | 5.9% | 58.4M | 59.4M | 66.0M | 11.8% |
| EPS | -0.67 | -0.54 | -0.66 | -0.27 | — | -0.20 | -0.27 | -0.26 | — |
| Shares | 34.6M | 34.6M | 37.8M | 41.8M | +20.8% | 42.1M | — | — | — |
| Debt | 0.8M | 38.5M | 38.8M | 39.3M | 267.0% | 39.6M | — | — | — |
| Equity | 37.6M | 26.7M | 14.2M | 14.5M | -27.1% | — | — | — | — |
| Op CF | -20.3M | -5.2M | -18.0M | -8.0M | — | -10.1M | — | — | — |
| Inv CF | -1.0M | 6.7M | -0.7M | -1.1M | — | — | — | — | — |
| Fin CF | 0.2M | 32.2M | 6.7M | 9.6M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of APYX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| APYX | Apyx Medical Corporation(you) | $130M | 18 | Strong Sell |
| QTRX | Quanterix Corporation | $125M | 14 | Strong Sell |
| OWLT | Owlet, Inc. | $146M | 15 | Strong Sell |
| LNSR | LENSAR, Inc. | $102M | 22 | Sell |
| QSI | Quantum-Si incorporated | $171M | 11 | Strong Sell |
| LAB | Standard BioTools Inc. | $252M | 18 | Strong Sell |
| SERA | Sera Prognostics, Inc. | $82M | 14 | Strong Sell |
| HYPR | Hyperfine, Inc. | $88M | 12 | Strong Sell |
| MXCT | MaxCyte, Inc. | $126M | 32 | Sell |
| LUNG | Pulmonx Corporation | $102M | 29 | Sell |
Peer medians: ROE -30.5% · P/E 27.0x · Gross margin 58.1%